Rockville, MD, United States of America

Y Shimohigashi

This inventor holds 1 USPTO granted patent. Top assignee: The United States of America as Represented by the Secretary of. Active years: 1984.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 1984

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Y Shimohigashi: Innovator in Enkephalin Research

Introduction

Y Shimohigashi is a notable inventor based in Rockville, MD (US). She has made significant contributions to the field of pharmacology, particularly in the development of compounds that interact with opiate receptors. Her work has implications for both research and therapeutic applications.

Latest Patents

Y Shimohigashi holds a patent for "Dimeric enkephalins." This invention involves symmetrical dimers of enkephalin polypeptides, which are linked at the C-termini with a difunctional amino bridging group. These compounds serve as valuable investigative tools for probing opiate receptor membranes. They are particularly useful as radiolabelled ligands for exploring the delta opiate receptor and have applications as narcotic and/or analgesic agents. She has 1 patent to her name.

Career Highlights

Y Shimohigashi works for the United States of America as Represented by the Secretary of. Her research has contributed to a deeper understanding of the mechanisms of opiate receptors and their potential therapeutic uses.

Collaborations

Throughout her career, Y Shimohigashi has collaborated with esteemed colleagues, including Hao-Chia Chen and Tommaso Costa. These partnerships have enhanced her research and expanded the impact of her inventions.

Conclusion

Y Shimohigashi's innovative work in the field of enkephalin research highlights her contributions to pharmacology and the development of new therapeutic agents. Her patent on dimeric enkephalins showcases her commitment to advancing scientific knowledge and improving healthcare outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…